Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646284 | 0.84 | PRMT1 (0.45) | PRMT1ADRA1AALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL23646236 | 0.82 | ITGB3 (0.48) | PRMT1ADRA1AEPHX2ALOX5MAPK1 | |
| SCHEMBL23646279 | 0.82 | ITGB3 (0.48) | PRMT1ADRA1AEPHX2ALOX5MAPK1 | |
| SCHEMBL23646286 | 0.82 | ITGB3 (0.48) | PRMT1ADRA1AEPHX2ALOX5MAPK1 | |
| SCHEMBL23646277 | 0.82 | ITGB3 (0.48) | PRMT1ADRA1AEPHX2ALOX5MAPK1 | |
| SCHEMBL23646230 | 0.78 | ALDH1A1 (0.35) | PRMT1ADRA1AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL20385914 | 0.75 | ADRA1A (0.49) | PRMT1ADRA1AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL5204373 | 0.73 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2FOLH1SIGMAR1 | |
| SCHEMBL6014048 | 0.72 | ADRA1A (0.42) | PRMT1ADRA1AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL25575666 | 0.72 | ADRA1A (0.42) | PRMT1ADRA1AALDH1A1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258324-B2 | Fatty acid analogues and methods of use | LIN BIOSCIENCE INC. (TW) | 2025-03-25 | — | — | US | disclosed |
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | LIN BIOSCIENCE INC. (TW) | 2021-07-22 | — | — | US | disclosed |
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | LIN BIOSCIENCE INC. (TW) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | ELOVL1, FADS1, ALOX5 | PRMT1 4275/4885ADRA1A 1498/4885ALDH1A1 1214/4885 |
| US-12258324-B2 | Fatty acid analogues and methods of use | ELOVL1, FADS1, ALOX5 | PRMT1 4275/4885ADRA1A 1498/4885ALDH1A1 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.